ChronoScale (CHRN) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
15 Oct, 2026Executive summary
Fiscal Q1 2027 revenue rose 148% YoY to $41.5M; continuing-operations net loss was $26.4M and Adjusted EBITDA was $5.9M.
Growth included a new customer’s AI hardware resale and related support and maintenance services.
Strategy shifted to cloud infrastructure after the September 30 sale of Legacy Ekso; major deployments require substantial financing and execution.
Financial highlights
Revenue was $41.5M vs. $16.7M YoY; cost of revenue increased 91% to $45.6M, including $22.4M of higher AI hardware purchases for resale.
Operating loss was $24.9M vs. $8.0M; continuing-operations net loss was $26.4M vs. $11.2M, or $0.18 per share vs. $0.08.
Total net loss was $42.5M, including $16.1M from discontinued operations.
SG&A rose to $20.7M from $0.4M, including $10.1M stock-based compensation and $4.6M transaction/project-related professional services.
Adjusted EBITDA was $5.9M; EBITDA was $(9.5)M.
Outlook and guidance
Two Q3 GPU services agreements provide $2.7B of contracted revenue over three years; related project-specific capex commitments are ~$2.3B over the next 12 months.
Customer commitments support a target of $1B annualized run-rate revenue by calendar Q3 2027; this is not a GAAP revenue forecast and actual results may differ materially.
Microsoft deployment targets ~50 MW of AI compute using NVIDIA GB300 NVL72 systems; delivery and commissioning depend on financing and development, construction, and operational milestones.
Baseten plans ~4 MW of AI compute capacity, with completion expected in calendar Q1 2027, subject to financing and customary project conditions.
Latest events from ChronoScale
- Seven directors remain on the ballot; Davis and Jones receive disposition-related separation benefits.CHRN
Proxy filing - A $500 million shelf backs cloud-focused growth and a conditional ~50 MW AI deployment plan.CHRN
Registration filing - Revenue fell 29% to $12.8M, net loss reached $11.7M, and a major business combination is pending.CHRN
Q4 2025 - Record Q4 revenue, improved margins, and narrowed net loss highlight strong operational progress.CHRN
Q4 2024 - Revenue fell 10% year-over-year, margins improved, but liquidity risks and funding needs remain.CHRN
Q1 2025 - Q2 revenue up 5%, margins improved, but going concern risk remains without new funding.CHRN
Q2 2024 - Q3 revenue dropped 10% YoY, net loss narrowed, and CMS reimbursement was achieved.CHRN
Q3 2024 - Q2 2025 revenue dropped 58% to $2.1M as Enterprise Health sales lagged, but Personal Health surged.CHRN
Q2 2025 - Q3 2025 revenue rose 2% YoY, gross margin hit 60.3%, and liquidity risks persist.CHRN
Q3 2025